ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Research Report 2026
Published Date: 2026-01-20
|
Report Code: QYRE-Auto-24C18464
Home | Market Reports | Health| Aging & Geriatrics
Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Research Report 2024
BUY CHAPTERS

Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Research Report 2026

Code: QYRE-Auto-24C18464
Report
2026-01-20
Pages:102
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Eli Lilly & Co
GE Healthcare Inc
Life Molecular Imaging Ltd.
Eli Lilly & Co

Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size

The global Diagnostic Radiopharmaceuticals for Alzheimer Disease market was valued at US$ 378 million in 2025 and is anticipated to reach US$ 857 million by 2032, at a CAGR of 12.6% from 2026 to 2032.

Diagnostic Radiopharmaceuticals for Alzheimer Disease Market

Diagnostic Radiopharmaceuticals for Alzheimer Disease Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Diagnostic Radiopharmaceuticals for Alzheimer Disease competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Radiodrugs for Alzheimer's disease (AD) are A class of radiotracers that are used to label beta-amyloid plaques (Aβ) or tau protein in the brain in positron emission tomography (PET) to assist doctors in early identification of AD, disease classification, and treatment response monitoring.
The North American market for Diagnostic Radiopharmaceuticals for Alzheimer Disease is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Diagnostic Radiopharmaceuticals for Alzheimer Disease is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Diagnostic Radiopharmaceuticals for Alzheimer Disease include Eli Lilly & Co., GE Healthcare, Inc., Life Molecular Imaging Ltd., etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Diagnostic Radiopharmaceuticals for Alzheimer Disease market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Diagnostic Radiopharmaceuticals for Alzheimer Disease. The Diagnostic Radiopharmaceuticals for Alzheimer Disease market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Diagnostic Radiopharmaceuticals for Alzheimer Disease market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Diagnostic Radiopharmaceuticals for Alzheimer Disease manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Report

Report Metric Details
Report Name Diagnostic Radiopharmaceuticals for Alzheimer Disease Market
Accounted market size in 2025 US$ 378 million
Forecasted market size in 2032 US$ 857 million
CAGR 12.6%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • Half Life:1.83 hours
  • Half Life:1 hours
by Application
  • Hospital
  • Clinic
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Eli Lilly & Co., GE Healthcare, Inc., Life Molecular Imaging Ltd.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Diagnostic Radiopharmaceuticals for Alzheimer Disease manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Diagnostic Radiopharmaceuticals for Alzheimer Disease sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Diagnostic Radiopharmaceuticals for Alzheimer Disease Market growing?

Ans: The Diagnostic Radiopharmaceuticals for Alzheimer Disease Market witnessing a CAGR of 12.6% during the forecast period 2026-2032.

What is the Diagnostic Radiopharmaceuticals for Alzheimer Disease Market size in 2032?

Ans: The Diagnostic Radiopharmaceuticals for Alzheimer Disease Market size in 2032 will be US$ 857 million.

Who are the main players in the Diagnostic Radiopharmaceuticals for Alzheimer Disease Market report?

Ans: The main players in the Diagnostic Radiopharmaceuticals for Alzheimer Disease Market are Eli Lilly & Co., GE Healthcare, Inc., Life Molecular Imaging Ltd.

What are the Application segmentation covered in the Diagnostic Radiopharmaceuticals for Alzheimer Disease Market report?

Ans: The Applications covered in the Diagnostic Radiopharmaceuticals for Alzheimer Disease Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Diagnostic Radiopharmaceuticals for Alzheimer Disease Market report?

Ans: The Types covered in the Diagnostic Radiopharmaceuticals for Alzheimer Disease Market report are Half Life:1.83 hours, Half Life:1 hours

1 Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Overview
1.1 Product Definition
1.2 Diagnostic Radiopharmaceuticals for Alzheimer Disease by Type
1.2.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Value by Type: 2025 vs 2032
1.2.2 Half Life:1.83 hours
1.2.3 Half Life:1 hours
1.3 Diagnostic Radiopharmaceuticals for Alzheimer Disease by Application
1.3.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Value by Application: 2025 vs 2032
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size Estimates and Forecasts
1.4.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue 2021–2032
1.4.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales 2021–2032
1.4.3 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Competition by Manufacturers
2.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Market Share by Manufacturers (2021–2026)
2.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Diagnostic Radiopharmaceuticals for Alzheimer Disease, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Diagnostic Radiopharmaceuticals for Alzheimer Disease, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Diagnostic Radiopharmaceuticals for Alzheimer Disease, Product Types and Applications
2.7 Global Key Manufacturers of Diagnostic Radiopharmaceuticals for Alzheimer Disease, Date of Entry into the Industry
2.8 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Competitive Situation and Trends
2.8.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Players Market Share by Revenue
2.8.3 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Scenario by Region
3.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Region: 2021–2032
3.2.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Region: 2021–2026
3.2.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Region: 2027–2032
3.3 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Region: 2021–2032
3.3.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Region: 2021–2026
3.3.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Region: 2027–2032
3.4 North America Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Facts & Figures by Country
3.4.1 North America Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Country (2021–2032)
3.4.3 North America Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Facts & Figures by Country
3.5.1 Europe Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Country (2021–2032)
3.5.3 Europe Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Facts & Figures by Region
3.6.1 Asia Pacific Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Region (2021–2032)
3.6.3 Asia Pacific Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Facts & Figures by Country
3.7.1 Latin America Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Country (2021–2032)
3.7.3 Latin America Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Facts & Figures by Country
3.8.1 Middle East and Africa Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Country (2021–2032)
3.8.3 Middle East and Africa Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Type (2021–2032)
4.1.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Type (2021–2026)
4.1.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Type (2027–2032)
4.1.3 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Market Share by Type (2021–2032)
4.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Type (2021–2032)
4.2.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Type (2021–2026)
4.2.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Type (2027–2032)
4.2.3 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Market Share by Type (2021–2032)
4.3 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Price by Type (2021–2032)
5 Segment by Application
5.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Application (2021–2032)
5.1.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Application (2021–2026)
5.1.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Application (2027–2032)
5.1.3 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Market Share by Application (2021–2032)
5.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Application (2021–2032)
5.2.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Application (2021–2026)
5.2.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Application (2027–2032)
5.2.3 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Market Share by Application (2021–2032)
5.3 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Eli Lilly & Co.
6.1.1 Eli Lilly & Co. Company Information
6.1.2 Eli Lilly & Co. Description and Business Overview
6.1.3 Eli Lilly & Co. Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Eli Lilly & Co. Diagnostic Radiopharmaceuticals for Alzheimer Disease Product Portfolio
6.1.5 Eli Lilly & Co. Recent Developments/Updates
6.2 GE Healthcare, Inc.
6.2.1 GE Healthcare, Inc. Company Information
6.2.2 GE Healthcare, Inc. Description and Business Overview
6.2.3 GE Healthcare, Inc. Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 GE Healthcare, Inc. Diagnostic Radiopharmaceuticals for Alzheimer Disease Product Portfolio
6.2.5 GE Healthcare, Inc. Recent Developments/Updates
6.3 Life Molecular Imaging Ltd.
6.3.1 Life Molecular Imaging Ltd. Company Information
6.3.2 Life Molecular Imaging Ltd. Description and Business Overview
6.3.3 Life Molecular Imaging Ltd. Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Life Molecular Imaging Ltd. Diagnostic Radiopharmaceuticals for Alzheimer Disease Product Portfolio
6.3.5 Life Molecular Imaging Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Diagnostic Radiopharmaceuticals for Alzheimer Disease Industry Chain Analysis
7.2 Diagnostic Radiopharmaceuticals for Alzheimer Disease Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Diagnostic Radiopharmaceuticals for Alzheimer Disease Production Mode & Process Analysis
7.4 Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales and Marketing
7.4.1 Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Channels
7.4.2 Diagnostic Radiopharmaceuticals for Alzheimer Disease Distributors
7.5 Diagnostic Radiopharmaceuticals for Alzheimer Disease Customer Analysis
8 Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Dynamics
8.1 Diagnostic Radiopharmaceuticals for Alzheimer Disease Industry Trends
8.2 Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Drivers
8.3 Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Challenges
8.4 Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Eli Lilly & Co
GE Healthcare Inc
Life Molecular Imaging Ltd.
Eli Lilly & Co
List of Tables
 Table 1. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales (K Units) of Key Manufacturers (2021–2026)
 Table 5. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Diagnostic Radiopharmaceuticals for Alzheimer Disease Average Price (US$/Unit) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Diagnostic Radiopharmaceuticals for Alzheimer Disease, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Diagnostic Radiopharmaceuticals for Alzheimer Disease, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Diagnostic Radiopharmaceuticals for Alzheimer Disease, Product Types and Applications
 Table 12. Global Key Manufacturers of Diagnostic Radiopharmaceuticals for Alzheimer Disease, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Companies by Tier (Tier 1, Tier 2, Tier 3), based on Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Region (K Units), 2021–2026
 Table 18. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Market Share by Region (2021–2026)
 Table 19. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Region (K Units), 2027–2032
 Table 20. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Market Share by Region (2027–2032)
 Table 21. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Market Share by Region (2021–2026)
 Table 23. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Market Share by Region (2027–2032)
 Table 25. North America Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Country (K Units), 2021–2026
 Table 27. North America Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Country (K Units), 2027–2032
 Table 28. North America Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Country (K Units), 2021–2026
 Table 32. Europe Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Country (K Units), 2027–2032
 Table 33. Europe Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Region (K Units), 2021–2026
 Table 37. Asia Pacific Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Region (K Units), 2027–2032
 Table 38. Asia Pacific Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Country (K Units), 2021–2026
 Table 42. Latin America Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Country (K Units), 2027–2032
 Table 43. Latin America Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Country (K Units), 2021–2026
 Table 47. Middle East and Africa Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Country (K Units), 2027–2032
 Table 48. Middle East and Africa Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales (K Units) by Type (2021–2026)
 Table 51. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales (K Units) by Type (2027–2032)
 Table 52. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Market Share by Type (2021–2026)
 Table 53. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Market Share by Type (2027–2032)
 Table 54. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Market Share by Type (2021–2026)
 Table 57. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Market Share by Type (2027–2032)
 Table 58. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Price (US$/Unit) by Type (2021–2026)
 Table 59. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Price (US$/Unit) by Type (2027–2032)
 Table 60. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales (K Units) by Application (2021–2026)
 Table 61. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales (K Units) by Application (2027–2032)
 Table 62. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Market Share by Application (2021–2026)
 Table 63. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Market Share by Application (2027–2032)
 Table 64. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Market Share by Application (2021–2026)
 Table 67. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Market Share by Application (2027–2032)
 Table 68. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Price (US$/Unit) by Application (2021–2026)
 Table 69. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Price (US$/Unit) by Application (2027–2032)
 Table 70. Eli Lilly & Co. Company Information
 Table 71. Eli Lilly & Co. Description and Business Overview
 Table 72. Eli Lilly & Co. Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 73. Eli Lilly & Co. Diagnostic Radiopharmaceuticals for Alzheimer Disease Product
 Table 74. Eli Lilly & Co. Recent Developments/Updates
 Table 75. GE Healthcare, Inc. Company Information
 Table 76. GE Healthcare, Inc. Description and Business Overview
 Table 77. GE Healthcare, Inc. Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 78. GE Healthcare, Inc. Diagnostic Radiopharmaceuticals for Alzheimer Disease Product
 Table 79. GE Healthcare, Inc. Recent Developments/Updates
 Table 80. Life Molecular Imaging Ltd. Company Information
 Table 81. Life Molecular Imaging Ltd. Description and Business Overview
 Table 82. Life Molecular Imaging Ltd. Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 83. Life Molecular Imaging Ltd. Diagnostic Radiopharmaceuticals for Alzheimer Disease Product
 Table 84. Life Molecular Imaging Ltd. Recent Developments/Updates
 Table 85. Key Raw Materials Lists
 Table 86. Raw Materials Key Suppliers Lists
 Table 87. Diagnostic Radiopharmaceuticals for Alzheimer Disease Distributors List
 Table 88. Diagnostic Radiopharmaceuticals for Alzheimer Disease Customers List
 Table 89. Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Trends
 Table 90. Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Drivers
 Table 91. Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Challenges
 Table 92. Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Restraints
 Table 93. Research Programs/Design for This Report
 Table 94. Key Data Information from Secondary Sources
 Table 95. Key Data Information from Primary Sources
 Table 96. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Diagnostic Radiopharmaceuticals for Alzheimer Disease
 Figure 2. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Share by Type: 2025 & 2032
 Figure 4. Half Life:1.83 hours Product Picture
 Figure 5. Half Life:1 hours Product Picture
 Figure 6. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Value by Application (US$ Million), 2021–2032
 Figure 7. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Share by Application: 2025 & 2032
 Figure 8. Hospital
 Figure 9. Clinic
 Figure 10. Others
 Figure 11. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 12. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size (US$ Million), 2021–2032
 Figure 13. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales (K Units), 2021–2032
 Figure 14. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Average Price (US$/Unit), 2021–2032
 Figure 15. Diagnostic Radiopharmaceuticals for Alzheimer Disease Report Years Considered
 Figure 16. Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Share by Manufacturers in 2025
 Figure 17. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Share by Manufacturers in 2025
 Figure 18. Top 5 and Top 10 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Players: Market Share by Revenue in Diagnostic Radiopharmaceuticals for Alzheimer Disease in 2025
 Figure 19. Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 20. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 21. North America Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Market Share by Country (2021–2032)
 Figure 22. North America Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Market Share by Country (2021–2032)
 Figure 23. United States Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Growth Rate (US$ Million), 2021–2032
 Figure 24. Canada Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Growth Rate (US$ Million), 2021–2032
 Figure 25. Europe Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Market Share by Country (2021–2032)
 Figure 26. Europe Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Market Share by Country (2021–2032)
 Figure 27. Germany Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Growth Rate (US$ Million), 2021–2032
 Figure 28. France Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Growth Rate (US$ Million), 2021–2032
 Figure 29. U.K. Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Growth Rate (US$ Million), 2021–2032
 Figure 30. Italy Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. Russia Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. Asia Pacific Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Market Share by Region (2021–2032)
 Figure 33. Asia Pacific Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Market Share by Region (2021–2032)
 Figure 34. China Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Growth Rate (US$ Million), 2021–2032
 Figure 35. Japan Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. South Korea Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. India Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. Australia Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. China Taiwan Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. Southeast Asia Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Latin America Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Market Share by Country (2021–2032)
 Figure 42. Latin America Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Market Share by Country (2021–2032)
 Figure 43. Mexico Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. Brazil Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. Argentina Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. Colombia Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Middle East and Africa Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Market Share by Country (2021–2032)
 Figure 48. Middle East and Africa Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Market Share by Country (2021–2032)
 Figure 49. Turkey Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. Saudi Arabia Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. UAE Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. Global Sales Market Share of Diagnostic Radiopharmaceuticals for Alzheimer Disease by Type (2021–2032)
 Figure 53. Global Revenue Market Share of Diagnostic Radiopharmaceuticals for Alzheimer Disease by Type (2021–2032)
 Figure 54. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Price (US$/Unit) by Type (2021–2032)
 Figure 55. Global Sales Market Share of Diagnostic Radiopharmaceuticals for Alzheimer Disease by Application (2021–2032)
 Figure 56. Global Revenue Market Share of Diagnostic Radiopharmaceuticals for Alzheimer Disease by Application (2021–2032)
 Figure 57. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Price (US$/Unit) by Application (2021–2032)
 Figure 58. Diagnostic Radiopharmaceuticals for Alzheimer Disease Value Chain
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

Global Blood based Detection Kit for Early Diagnosis of Alzheimer s Disease Market Research Report 2024
Global Monoclonal Antibodies for Alzheimer Disease Market Research Report 2024
Global Medications for Alzheimer s Disease Market Research Report 2024
Global Alzheimer s Disease Blood Diagnostic Market Research Report 2024
Global Alzheimer s Disease Blood Test Kit Market Research Report 2024
Global Alzheimer s Disease Diagnosis Market Research Report 2024
Global Radiopharmaceuticals for Diagnosis Market Research Report 2024
Global Alzheimer s Disease Drug Market Insights Forecast to 2030
Global Anti amyloid Drugs Market Research Report 2024
Global Alzheimer s Disease Therapeutics and Diagnostics Market Insights Forecast to 2030
Global Alzheimer Treatment Drug Market Research Report 2025
Global Alzheimer s Blood Tests Market Research Report 2024
Global Blood Tests for Alzheimer s Diagnosis Market Research Report 2024
Global Nuclear Medicine Radiopharmaceuticals Market Research Report 2024
Global Diagnostic Radiopharmaceuticals Market Research Report 2024
Global Aβ PET Tracer Market Research Report 2024
Global SPECT and PET Radiopharmaceuticals Market Research Report 2024
Global Aβ Monoclonal Antibody Drug Market Research Report 2024
Alzheimer s Disease Diagnostic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Cholinesterase Inhibitors for Alzheimer s Disease Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions